This study was designed to evaluate the activity of the specific AKT inhibitor GSK2141795 [9] alone and in combination with platinum in platinum-resistant ovarian cancer and to guide the clinical development of AKT inhibition by identifying protein-based and imaging-based predictive and pharmacodynamic biomarkers. The gene discussed is AKT1; the disease is ovarian carcinoma.